DK2776065T3 - Kombinationsterapier ved anvendelse af anti-pseudomonas-psl- og pcrv-bindende molekyler - Google Patents

Kombinationsterapier ved anvendelse af anti-pseudomonas-psl- og pcrv-bindende molekyler Download PDF

Info

Publication number
DK2776065T3
DK2776065T3 DK12847479.8T DK12847479T DK2776065T3 DK 2776065 T3 DK2776065 T3 DK 2776065T3 DK 12847479 T DK12847479 T DK 12847479T DK 2776065 T3 DK2776065 T3 DK 2776065T3
Authority
DK
Denmark
Prior art keywords
binding molecules
combination therapies
pseudomonas psl
pcrv binding
pcrv
Prior art date
Application number
DK12847479.8T
Other languages
Danish (da)
English (en)
Inventor
Antonio Digiandomenico
Paul Warrener
Charles Stover
Nazzareno Dimasi
Ryan Fleming
Binyam Bezabeh
Changshou Gao
Cuihua Gao
Godfrey Rainey
Bret Sellman
Sandrine Guillard
Steven Rust
Mladen Tomich
Vignesh Venkatraman
Reena Varkey
Li Peng
Melissa Damschroder
Partha Chowdhury
Ralph Minter
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Application granted granted Critical
Publication of DK2776065T3 publication Critical patent/DK2776065T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK12847479.8T 2011-11-07 2012-11-06 Kombinationsterapier ved anvendelse af anti-pseudomonas-psl- og pcrv-bindende molekyler DK2776065T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161556645P 2011-11-07 2011-11-07
US201261625299P 2012-04-17 2012-04-17
US201261697585P 2012-09-06 2012-09-06
PCT/US2012/063722 WO2013070615A1 (en) 2011-11-07 2012-11-06 Combination therapies using anti- pseudomonas psl and pcrv binding molecules

Publications (1)

Publication Number Publication Date
DK2776065T3 true DK2776065T3 (da) 2020-10-12

Family

ID=48290482

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12847479.8T DK2776065T3 (da) 2011-11-07 2012-11-06 Kombinationsterapier ved anvendelse af anti-pseudomonas-psl- og pcrv-bindende molekyler

Country Status (22)

Country Link
US (4) US10597439B2 (https=)
EP (1) EP2776065B1 (https=)
JP (1) JP6182152B2 (https=)
KR (1) KR102184343B1 (https=)
CN (1) CN104136042B (https=)
AU (3) AU2012336028A1 (https=)
BR (1) BR112014011028B1 (https=)
CA (2) CA3161431A1 (https=)
CY (1) CY1123552T1 (https=)
DK (1) DK2776065T3 (https=)
ES (1) ES2859323T3 (https=)
HR (1) HRP20201370T1 (https=)
HU (1) HUE050985T2 (https=)
LT (1) LT2776065T (https=)
MX (1) MX374826B (https=)
PL (1) PL2776065T3 (https=)
PT (1) PT2776065T (https=)
RS (1) RS60920B1 (https=)
RU (1) RU2687588C2 (https=)
SI (1) SI2776065T1 (https=)
SM (1) SMT202000542T1 (https=)
WO (1) WO2013070615A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014100111A (ru) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HRP20201370T1 (hr) * 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
EP2820043B1 (en) * 2012-03-02 2020-01-15 Ablynx N.V. Biparatopic pseudomonas aeruginosa pcrv binding single variable domain antibodies
BR112015010240A2 (pt) * 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
EP3001838A4 (en) 2013-05-14 2017-02-08 Medlmmune, LLC Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses therof
WO2015171504A1 (en) * 2014-05-05 2015-11-12 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
ES2846881T3 (es) * 2015-05-01 2021-07-30 Inhibrx Inc Moléculas que se dirigen al sistema de secreción de tipo III
RU2018107056A (ru) * 2015-08-24 2019-09-26 МЕДИММЬЮН, ЭлЭлСи Полипептиды mrka, антитела к ним и пути их применения
WO2017095744A1 (en) 2015-11-30 2017-06-08 Medimmune, Llc Method for preventing or treating nosocomial pneumonia
SG11201809778TA (en) 2016-05-05 2018-12-28 Univ Pennsylvania Dna antibody constructs for use against pseudomonas aeruginosa
EP3983015A1 (en) * 2019-06-11 2022-04-20 Regeneron Pharmaceuticals, Inc. Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
MY208387A (en) * 2019-07-09 2025-05-05 Beijing Solobio Genetechnology Co Ltd Antibodies specifically recognizing pseudomonas pcrv and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN118620074A (zh) * 2020-06-01 2024-09-10 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途
AU2021323178B2 (en) * 2020-08-07 2025-05-08 Beijing Solobio Genetechnology Co., Ltd. Antibodies specifically recognizing pseudomonas PsL and uses thereof
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
KR20230109703A (ko) * 2020-11-18 2023-07-20 베이징 솔로바이오 진테크놀로지 컴퍼니 리미티드 슈도모나스 pcrv 및 psl을 특이적으로 식별하는 항체 결합을 포함하는 항체 조합 및 이중특이성 항체
US20250388669A1 (en) * 2022-01-21 2025-12-25 Jieyi Wang Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation
JP2025521777A (ja) 2022-06-29 2025-07-10 アストラゼネカ・アクチエボラーグ 気管支拡張症の治療のための抗ｐｃｒｖ及びｐｓｌ二重特異性抗体
WO2024231440A1 (en) 2023-05-09 2024-11-14 Astrazeneca Ab Bispecific anti-pseudomonas antibodies with modified fc regions and methods of use thereof
AU2024307442A1 (en) 2023-06-28 2026-02-19 Universität Zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU584690B2 (en) 1985-03-11 1989-06-01 Teijin Limited E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
WO1999004705A1 (en) 1997-07-25 1999-02-04 Tsui Ban C H Devices, systems and methods for determining proper placement of epidural catheters
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
EP1666058B1 (en) 1998-11-25 2011-12-28 MCW Research Foundation, Incorporated Method of diagnosing a Pseudomonas aeruginosa infection
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
WO2002064161A2 (en) * 2001-01-26 2002-08-22 Mcw Research Foundation, Inc. Method and compositions for immunization with the pseudomonas v antigen
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20020146753A1 (en) * 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US20030232387A1 (en) * 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
JP2008133206A (ja) * 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
BRPI0819598A2 (pt) * 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
EA020544B1 (ru) * 2008-01-10 2014-12-30 Шионоги Энд Ко., Лтд. АНТИТЕЛА ПРОТИВ PcrV
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
RU2011126338A (ru) 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2679515B1 (en) * 2008-12-31 2014-07-02 W.L. Gore & Associates GmbH Venting device
CA2751433A1 (en) * 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
SG174225A1 (en) * 2009-03-11 2011-10-28 Shionogi & Co Humanized pcrv antibody having anti-pseudomonal activity
EP2408475B1 (en) * 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2417157A1 (en) 2009-04-09 2012-02-15 Kenta Biotech AG Human monoclonal antibody specific for lipolysaccarides (lps) of serotype lats 01 of pseudomonas aeruginosa
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
WO2011087799A1 (en) 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
WO2012145626A1 (en) 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
RU2014100111A (ru) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HRP20201370T1 (hr) * 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
EP2820043B1 (en) * 2012-03-02 2020-01-15 Ablynx N.V. Biparatopic pseudomonas aeruginosa pcrv binding single variable domain antibodies
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
BR112015010240A2 (pt) * 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
KR20210083389A (ko) 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
EP3001838A4 (en) 2013-05-14 2017-02-08 Medlmmune, LLC Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses therof
WO2015171504A1 (en) * 2014-05-05 2015-11-12 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017095744A1 (en) * 2015-11-30 2017-06-08 Medimmune, Llc Method for preventing or treating nosocomial pneumonia
SG11201809778TA (en) * 2016-05-05 2018-12-28 Univ Pennsylvania Dna antibody constructs for use against pseudomonas aeruginosa
EP3983015A1 (en) * 2019-06-11 2022-04-20 Regeneron Pharmaceuticals, Inc. Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof

Also Published As

Publication number Publication date
SMT202000542T1 (it) 2020-11-10
ES2859323T3 (es) 2021-10-01
CA3161431A1 (en) 2013-05-16
RS60920B1 (sr) 2020-11-30
AU2012336028A1 (en) 2014-06-26
LT2776065T (lt) 2020-10-12
EP2776065B1 (en) 2020-08-05
JP2015504421A (ja) 2015-02-12
SI2776065T1 (sl) 2020-10-30
BR112014011028A2 (pt) 2017-05-02
NZ624072A (en) 2016-09-30
EP2776065A4 (en) 2016-03-02
US10597439B2 (en) 2020-03-24
CN104136042A (zh) 2014-11-05
US20200317757A1 (en) 2020-10-08
AU2017219081B2 (en) 2019-06-06
AU2017219081B9 (en) 2019-07-04
CA2854817A1 (en) 2013-05-16
EP2776065A1 (en) 2014-09-17
US20250243262A1 (en) 2025-07-31
CY1123552T1 (el) 2022-03-24
HRP20201370T1 (hr) 2020-11-27
RU2014122990A (ru) 2015-12-20
US20220177554A1 (en) 2022-06-09
PL2776065T3 (pl) 2020-12-14
HK1201453A1 (en) 2015-09-04
KR102184343B1 (ko) 2020-11-30
PT2776065T (pt) 2020-09-25
CA2854817C (en) 2022-08-16
AU2017219081A1 (en) 2017-09-14
RU2687588C2 (ru) 2019-05-15
NZ722379A (en) 2019-12-20
MX374826B (es) 2025-03-06
AU2019226205A1 (en) 2019-09-26
US12428473B2 (en) 2025-09-30
US20150023966A1 (en) 2015-01-22
CN104136042B (zh) 2017-08-18
BR112014011028B1 (pt) 2021-03-02
JP6182152B2 (ja) 2017-08-16
HUE050985T2 (hu) 2021-01-28
WO2013070615A8 (en) 2013-06-20
US11203633B2 (en) 2021-12-21
KR20140091736A (ko) 2014-07-22
WO2013070615A1 (en) 2013-05-16
MX2014005566A (es) 2014-10-14

Similar Documents

Publication Publication Date Title
DK2776065T3 (da) Kombinationsterapier ved anvendelse af anti-pseudomonas-psl- og pcrv-bindende molekyler
IL288203A (en) Meditopes and meditope-binding antibodies and uses thereof
CY2023014I1 (el) Αντι il-36r αντισωματα
FR23C1013I1 (fr) Molécules de liaison pour bcma et cd3
LTC2521568I2 (lt) Plazmos kalikreiną surišantys baltymai
HRP20181553T1 (hr) Molekule koje se vežu na anti-alfa-sinuklein
HRP20180458T1 (hr) Molekule koje vežu anti-pseudomonas psl i njihova uporaba
HUE041958T2 (hu) 4-IBB-t kötõ molekulák
DK2683406T3 (da) Anti-cd40-antistoffer og anvendelser deraf
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
CO6811812A2 (es) Anticuerpo anti-b7-h3
CO7020862A2 (es) Proteinas de unión al antígeno cd27l
PL3415531T3 (pl) Białka wiążące antygen
CR20140127A (es) Anticuerpo anti-abtcr
EP2692810A4 (en) BINDING COMPOSITION AND PAPER
SG11201502937PA (en) COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
EP2529947A4 (en) BINDER
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną
EP2701889A4 (en) Bonding process
CO6841994A2 (es) Anticuerpos
FI9197U1 (fi) Sideosa ja kotelo
GB201117182D0 (en) Anti-notch antibody molecules and uses thereof